DCPH
Deciphera Pharmaceuticals Inc
Halal Rating :
Last Price
$25.60
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Deciphera Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. The company's lead product, QINLOCK® (ripretinib), is approved globally for the treatment of fourth-line gastrointestinal stromal tumor (GIST). Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2024 | $45.0m | $93.85m | - | - | 0.00% | 0.00% |
| Dec. 31, 2023 | $48.29m | $99.53m | - | - | 0.00% | 0.00% |
| Sept. 30, 2023 | $43.31m | $97.0m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Deciphera Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.